Shire to buy Baxalta for US$32bn


Creating a global leader in rare diseases

Shire has agreed a US$32bn takeover of Baxalta.

Under the agreement, Dublin-based Shire will pay $47.50 a share for Baxalta, which represents a 37.5% premium over the US company's share price before Shire's initial offer on 3 August 2015.

The transaction is expected to close in the middle of this year.

Flemming Ornskov, Shire's Chief Executive, said a combination of the two companies would create the leading biotechnology company focused on treatments for rare diseases, with projected revenues of more than $20bn by 2020.

'Together, we will have leadership positions in multiple, high-value franchises and become the clear partner of choice in rare diseases,' he said.

Shire also anticipates that it will realise more than $500m in annual cost savings (expected to be achieved within the first three years after completion) by increasing efficiencies, leveraging the scale of the combined business and optimising the combined R&D portfolio.

Baxalta's Chief Executive Ludwig Hantson, who in August last year said the deal was not in the best interests of Baxalta shareholders, said the transaction presented a 'unique opportunity for Baxalta shareholders, who will receive substantial immediate value as well as an ongoing stake in a combined global leader in rare diseases with strong growth prospects'.

The combined company will have products in the multi-billion dollar franchises of Haematology; Immunology; Neuroscience; Lysosomal Storage Diseases; Gastrointestinal/Endocrine; and Hereditary Angioedema (HAE). It will also have a growing franchise in Oncology, with approved products and innovative compounds in development, as well as a robust late-stage Ophthalmics pipeline.

Sign up for your free email newsletter

Further, the combined company will benefit from expanded geographic reach across more than 100 countries. In total, the proposed combination will create a sustainable platform for future innovation and growth, yielding projected near- and long-term value for shareholders, the firms said.